Boceprevir

AdipoGen Life Sciences
Product Code: AG-CR1-3735

CodeSizePrice
AG-CR1-3735-M0055 mg£70.00
Quantity:
AG-CR1-3735-M01010 mg£105.00
Quantity:
AG-CR1-3735-M05050 mg£200.00
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO

Images

1 / 1
Chemical Structure

Chemical Structure

Further Information

Alternate Names/Synonyms:
Victrelis; EBP 520; SCH 503034
Appearance:
White to off-white solid.
CAS:
394730-60-0
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07,GHS08
Handling Advice:
Keep cool and dry.
Hazards:
H302, H361
InChi:
InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
InChiKey:
LHHCSNFAOIFYRV-DOVBMPENSA-N
Long Description:
Chemical. CAS: 394730-60-0. Formula: C27H45N5O5. MW: 519.7. The antiviral agent boceprevir is a protease inhibitor that covalently and reversibly binds to the catalytic site (Ser139) of hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A), a serine protease that is essential for viral replication (Ki = 14nM) by cleaving the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B. It inhibits the NS3/4A protease in an in vitro HCV replicon system with an EC50 value of 200 nM. Boceprevir has been identified as a potential inhibitor of SARS-CoV-2 responsible for COVID-19. It inhibits SARS-CoV-2 viral replication by targeting the viral main protease Mpro (IC50 = 4.13µM).
MDL:
MFCD22208555
Molecular Formula:
C27H45N5O5
Molecular Weight:
519.7
Package Type:
Vial
Precautions:
P301+P312; P308+P313
Product Description:
The antiviral agent boceprevir is a protease inhibitor that covalently and reversibly binds to the catalytic site (Ser139) of hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A), a serine protease that is essential for viral replication (Ki = 14nM) by cleaving the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B. It inhibits the NS3/4A protease in an in vitro HCV replicon system with an EC50 value of 200 nM. Boceprevir has been identified as a potential inhibitor of SARS-CoV-2 responsible for COVID-19. It inhibits SARS-CoV-2 viral replication by targeting the viral main protease Mpro (IC50 = 4.13µM).
Purity:
>95% (NMR)
Signal word:
Warning
SMILES:
[H][C@]1(C2(C)C)[C@]2([H])CN(C([C@H](C(C)(C)C)NC(NC(C)(C)C)=O)=O)[C@]1([H])C(NC(CC3CCC3)C(C(N)=O)=O)=O
Solubility Chemicals:
Soluble in DMSO (15mg/ml), ethanol (20mg/ml) or DMF (20mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

SCH 503034, a mechanism-based inhibitor of Hepatitis C Virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells: B.A. Malcolm, et al.; Antimicrob. Agents Chemother. 50, 1013 (2006) | Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections: S. Venkatraman; Trends Pharmacol. Sci. 33, 289 (2012) (Review) | The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease: A.Y. Howe & S. Venkatraman; J. Clin. Transl. Hepatol. 1, 22 (2013) (Review) | Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease: C. Ma, et al.; bioRxiv (Preprint) (2020)